XSTO
QUIA
Market cap135kUSD
Dec 15, Last price
0.00SEK
Name
QuiaPEG Pharmaceuticals Holding AB
Chart & Performance
P/E
—
P/S
2.85
EPS
—
Div Yield, %
—
Shrs. gr., 5y
253.75%
Rev. gr., 5y
5.31%
Revenues
460k
-89.48%
Net income
-29m
L+75.08%
CFO
-10m
L-0.93%
Dividend
Mar 30, 20172.3915 SEK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Quia Pharma AB specializes in the research, development, and commercialization of advanced drug delivery systems. Its core product, Uni-Qleaver®, utilizes a pioneering releasable pegylation technology. This innovative approach effectively mitigates common drawbacks and allows for the precise modulation of a drug's half-life. The company, established by Marek Kwiatkowski, is headquartered in Uppsala, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||